Circassia Pharmaceuticals Share Price (CIR)

77.15 -1.85 (-2.34%) delayed: 3:26PM BST
Bid price 76.10 Open price 80.76
Ask price 78.20 Prev close 79.00
High price 80.76 Spread 2.69%
Low price 76.79 Volume 21,673

Register now for FREE live Circassia Pharmaceuticals share prices, Circassia Pharmaceuticals stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Circassia Pharmaceuticals Level 2 Data, indepth research tools and investor commentary for Circassia Pharmaceuticals (CIR) and other London Stock Exchange equities.

Circassia Pharmaceuticals Share Price Chart

Advanced Charts >>

Register now for FREE Circassia Pharmaceuticals share price charts

Circassia Pharmaceuticals Share Price Information

Name Circassia Pharmaceuticals Epic CIR
Sector Pharmaceuticals & Biotechnology ISIN GB00BJVD3B28
Activites Circassia Pharmaceuticals plc is a world-class specialty pharmaceutical business focused on respiratory disease. In addition to its market-leading NIOX products, the Company recently established a collaboration with AstraZeneca in the US in which it promotes the chronic obstructive pulmonary disease (COPD) treatment Tudorza, and has the US commercial rights to late-stage COPD product Duaklir. Circassia's development pipeline includes a range of respiratory medicines. The Company's lead asthma treatment targets substitution of GSK's Flixotide pMDI and was approved in the UK. Circassia is also developing a direct substitute for Seretide pMDI, and its pipeline includes a number of inhaled medicines for COPD, including single and combination dose products. Index n/a

Circassia Pharmaceuticals Key Numbers

Latest Share Price (p) 77.15 Net Gearing (%) 33.08
Market Capitalisation (£m) 282.18 Gross Gearing (%) 44.14
Shares in issue (m) 357.19 Debt Ratio 39.51
P/E Ratio -2.55 Debt-to-Equity Ratio 0.83
Total dividends per share (p) 0.00 Assets / Equity Ratio 1.79
Dividend Yield (%) 0.00 Price to book value 1.26
Dividend cover (x) 0.00 ROCE (%) -30.57
Earning per share (p) -31.00 EPS Growth (%) 35.42
52 week high / low 113.50 / 71.20 DPS Growth (%) n/a

Circassia Pharmaceuticals Director Deals

Dec.Date Type Director Pos No. of Shares
17/07/2017 EXR Steven Harris CEO 535,375
18/09/2015 SELL Charles Swingland RES 1,230,000
18/09/2015 SELL Charles Swingland RES 9,000
18/09/2015 SELL Charles Swingland RES 754,548
27/03/2014 EXR Dr Rod Hafner ED 212,375

More Circassia Pharmaceuticals Director Deals >>

Circassia Pharmaceuticals Company News

16:25 16/08/2018

Director Declaration

RNS Number : 0777Y Circassia Pharmaceuticals Plc 16 August 2018   16 August 2018   Circassia Pharmaceuticals plc   Listing Rule 9.6.14(R) Disclosure   Circassia Pharmaceuticals plc (the "Company") announces in accordance with Listing Rule 9.6.14(R)...

07:00 13/08/2018

Regulatory Application

RNS Number : 5384X Circassia Pharmaceuticals Plc 13 August 2018   Circassia Announces Duaklir® New Drug Application (NDA) and Tudorza® Supplemental NDA Accepted for Review by FDA   Ø PDUFA target action date of 31 March 2019 confirmed for both filings...

07:00 31/07/2018

Total Voting Rights

RNS Number : 0568W Circassia Pharmaceuticals Plc 31 July 2018   For immediate release   Circassia Pharmaceuticals plc   Total Voting Rights Update       31st July 2018   In accordance with the requirements of the FCA's Disclosure and...

More Circassia Pharmaceuticals Company News >>

Register now for FREE Circassia Pharmaceuticals company news

Circassia Pharmaceuticals Share Price Discussions

No Circassia Pharmaceuticals Share Price Discussions

Register now for FREE Circassia Pharmaceuticals share price discussions